Intrauterine Treatment of a Fetus with Familial Hypertrophic Cardiomyopathy Secondary to MYH7 Mutation

Meghan G. Hill, Mehtab K. Sekhon, Kathryn L. Reed, Caroline F. Anderson, Nydia D. Borjon, Jil C. Tardiff, Brent J. Barber

Research output: Contribution to journalArticle


There is no clear consensus on optimal management of fetuses affected by familial hypertrophic cardiomyopathy (HCM). Intrauterine treatment of the condition has not been attempted in any standardized fashion. We report the case of a fetus treated by maternal propranolol during the third trimester after septal hypertrophy and diastolic dysfunction was diagnosed on fetal echocardiogram. The pregnancy went successfully to term, and fetal septal hypertrophy was noted to improve prior to delivery.

Original languageEnglish (US)
Pages (from-to)1774-1777
Number of pages4
JournalPediatric Cardiology
Issue number8
Publication statusPublished - Dec 1 2015



  • Beta myosin mutation
  • Fetal echocardiography
  • Fetal hypertrophic cardiomyopathy
  • Propranolol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this